EGFR and non-small cell lung carcinoma: KCSG-LU15-09 study reported that patients with uncommon EGFR mutations taking osimertinib 80 mg orally once per day could achieve an intracranial ORR of 40.0% (2/5) [25].Several studies have demonstrated the potential efficacy of dacomitinib in EGFR-positive NSCLC with CNS metastases, with ORR ranging from 87.5% to 92.9% and DCR of 100% [30–33].